Paliperidone Liconsa
Long-Acting Atypical Antipsychotic – Once-Monthly Depot Injection
Paliperidone Liconsa is a generic long-acting injectable (depot) formulation of paliperidone palmitate, marketed by Laboratorios Liconsa as a prolonged-release suspension for intramuscular injection in a pre-filled syringe. Paliperidone is an atypical (second-generation) antipsychotic and the principal active metabolite of risperidone. It is approved for the maintenance treatment of schizophrenia in adults who have already been stabilized on oral paliperidone or oral risperidone, and – in selected patients with established tolerability – for the treatment of acute schizophrenia. The once-monthly dosing schedule is designed to support consistent symptom control, reduce the burden of daily oral medication, and improve long-term adherence, a key factor in preventing relapse. Paliperidone Liconsa 25 mg is the lowest of the monthly maintenance strengths and is typically reserved for patients who have demonstrated a clinical response at low plasma concentrations or who require a dose reduction due to tolerability.
Quick Facts: Paliperidone Liconsa
Key Takeaways
- Paliperidone Liconsa is a generic paliperidone palmitate long-acting injectable (LAI) used for the maintenance treatment of schizophrenia in adults, administered once every month by a healthcare professional.
- Paliperidone is the principal active metabolite of risperidone and acts mainly by blocking dopamine D2 and serotonin 5-HT2A receptors, reducing positive symptoms (hallucinations, delusions) while minimizing extrapyramidal effects compared with first-generation antipsychotics.
- Treatment typically starts with two deltoid loading doses – 150 mg on day 1 and 100 mg on day 8 – followed by a monthly maintenance dose between 25 mg and 150 mg, individualized to the patient.
- Because the active substance persists in the body for weeks after injection, side effects such as injection-site reactions, weight gain, sedation, parkinsonism, akathisia or elevated prolactin may continue for some time after a dose, and cannot be rapidly reversed by stopping the medicine.
- Elderly patients with dementia-related psychosis treated with antipsychotics have an increased risk of death and stroke; Paliperidone Liconsa is not approved for this indication.
What Is Paliperidone Liconsa and What Is It Used For?
Paliperidone Liconsa belongs to the group of medicines known as atypical (second-generation) antipsychotics. The active substance, paliperidone palmitate, is a palmitic acid ester of paliperidone that is slowly hydrolysed after intramuscular injection to release paliperidone (chemically, 9-hydroxyrisperidone). Paliperidone itself is the main active metabolite formed in the body from oral risperidone, and it shares most of its pharmacological properties. Paliperidone Liconsa is a generic version of the paliperidone palmitate once-monthly injection originally marketed under the brand names Xeplion (European Union) and Invega Sustenna (United States), and has been authorised on the basis of bioequivalence to the reference product.
Paliperidone produces its antipsychotic effect primarily through a combination of dopamine D2 receptor antagonism and serotonin 5-HT2A receptor antagonism in the central nervous system. Excess dopaminergic activity in the mesolimbic pathway is thought to contribute to positive psychotic symptoms such as hallucinations and delusions; blockade of D2 receptors in this pathway therefore reduces these symptoms. Simultaneous blockade of 5-HT2A receptors in the cortex helps modulate dopamine release in other brain areas and is thought to lower the risk of extrapyramidal motor side effects while also contributing to effects on mood and cognition. Paliperidone also has affinity for alpha-1 and alpha-2 adrenergic receptors (which can contribute to orthostatic hypotension) and histamine H1 receptors (which may contribute to sedation and weight gain). Unlike some other antipsychotics, paliperidone does not show appreciable binding to cholinergic muscarinic receptors or beta-1 and beta-2 adrenergic receptors.
The licensed indications for the once-monthly paliperidone palmitate injection, including Paliperidone Liconsa, are as follows:
- Maintenance treatment of schizophrenia in adults: for patients (18 years or older) who have already been clinically stabilised with oral paliperidone or oral risperidone. This is the most common use. The goal of maintenance therapy is to reduce the risk of relapse, stabilise functioning, and support recovery.
- Acute treatment of schizophrenia in adults: in selected patients with a known history of tolerability to oral paliperidone or risperidone, the once-monthly injection can be initiated without prior oral stabilisation using an initiation schedule designed to rapidly achieve therapeutic plasma concentrations.
A central clinical rationale for long-acting injectable antipsychotics such as Paliperidone Liconsa is adherence support. In schizophrenia, non-adherence to daily oral medication is a leading cause of relapse and rehospitalisation. Because paliperidone palmitate delivers therapeutic plasma concentrations for approximately one month from a single injection, the risk of inadvertent missed doses – and of silent, incremental non-adherence – is substantially reduced. Patient, carer and clinician reviews consistently highlight this as one of the key practical advantages compared with daily oral regimens.
Paliperidone Liconsa 25 mg is the lowest available strength of the once-monthly formulation. In practice, the 25 mg dose is typically used as a maintenance dose in patients who have shown a good clinical response to low paliperidone plasma concentrations, in patients with moderate renal impairment in whom dose reduction is required, or in patients where tolerability concerns have prompted a reduction from higher maintenance doses such as 50 mg, 75 mg, 100 mg or 150 mg. It is not generally used as a loading dose; the initiation schedule uses 150 mg on day 1 and 100 mg on day 8 in the deltoid muscle.
Paliperidone palmitate is virtually insoluble in water. After intramuscular injection, it forms a depot at the injection site from which it is slowly released and hydrolysed by tissue esterases to paliperidone. This controlled release produces therapeutic plasma concentrations from around day 4 onwards (after deltoid loading) and sustains them for roughly one month, eliminating peaks and troughs associated with daily oral dosing. Peak plasma concentrations after injection are reached at approximately 13 days on average, and the apparent half-life ranges from 25 to 49 days depending on the site and dose.
What Should You Know Before Receiving Paliperidone Liconsa?
Because Paliperidone Liconsa is a long-acting injection, the medicine cannot be rapidly removed from the body if a problem occurs. A careful, thorough assessment before starting is therefore especially important. This includes a full medical history, medication review, cardiovascular assessment (often including an electrocardiogram in higher-risk patients), and baseline measurement of weight, blood glucose, lipid profile and, where clinically appropriate, prolactin.
In almost all patients, oral tolerability must be established first. Because paliperidone is the main active metabolite of risperidone, previous successful and well-tolerated treatment with oral paliperidone or oral risperidone is usually considered sufficient. If you have never taken either of these medicines, an oral trial is generally recommended before committing to the long-acting injectable.
Contraindications
Paliperidone Liconsa should not be used in patients with:
- Known hypersensitivity to paliperidone, risperidone or any of the excipients listed in the product information. Signs of a hypersensitivity reaction may include rash, itching, swelling of the face, lips or tongue, difficulty breathing, or a sudden drop in blood pressure.
Additional contraindications may apply locally depending on national prescribing information and patient-specific circumstances; always refer to the latest Summary of Product Characteristics and your prescribing physician’s advice.
Elderly patients with dementia-related psychosis treated with antipsychotics, including paliperidone, are at an increased risk of death and cerebrovascular adverse events (including stroke and transient ischaemic attack). Paliperidone Liconsa is not approved for the treatment of dementia-related psychosis. Non-pharmacological approaches should always be tried first for behavioural symptoms of dementia, and specialist assessment is required if antipsychotic treatment is being considered.
Warnings and Precautions
Tell your doctor before receiving Paliperidone Liconsa if any of the following apply, as they may require closer monitoring, dose adjustment, or careful risk-benefit assessment:
- Cardiovascular disease: Including known heart disease, heart failure, recent myocardial infarction, conduction abnormalities, or a family history of sudden cardiac death. Paliperidone can cause QT-interval prolongation and has been associated with orthostatic hypotension.
- Risk factors for stroke: High blood pressure, atrial fibrillation, carotid disease, prior stroke or transient ischaemic attack. This is especially relevant in elderly patients.
- Parkinson’s disease or Lewy body dementia: Paliperidone can worsen motor symptoms and, as with other antipsychotics, may cause severe sensitivity reactions in patients with these conditions, including neuroleptic malignant syndrome-like signs and marked parkinsonism.
- Neuroleptic malignant syndrome (NMS): A rare but life-threatening syndrome of hyperthermia, rigidity, altered consciousness and autonomic instability has been reported with antipsychotics. Any personal history of NMS must be disclosed.
- Tardive dyskinesia: Antipsychotics can cause tardive dyskinesia, a syndrome of potentially irreversible involuntary movements. Long duration of treatment and higher cumulative doses increase the risk; the very long plasma persistence of the depot formulation is relevant when planning long-term therapy.
- Seizures: Paliperidone may lower the seizure threshold. If you have a history of seizures or conditions associated with lowered threshold, closer monitoring is required.
- Diabetes or risk factors for diabetes: Paliperidone can cause hyperglycaemia, new-onset diabetes mellitus or worsening of existing diabetes, including (rarely) diabetic ketoacidosis and hyperosmolar coma. Baseline and periodic monitoring of fasting blood glucose and HbA1c is recommended.
- Weight gain, dyslipidaemia and metabolic syndrome: Significant weight gain and changes in lipid profile have been reported. Baseline weight, waist circumference and lipid panel, with periodic reassessment, are part of standard antipsychotic monitoring.
- Hyperprolactinaemia: Like risperidone, paliperidone reliably raises prolactin. Long-standing elevation may cause menstrual irregularities, galactorrhoea, sexual dysfunction, gynaecomastia and, potentially, reduced bone mineral density. Caution is advised in patients with a history of breast cancer or other possibly prolactin-dependent tumours.
- Renal impairment: Paliperidone is predominantly excreted unchanged in urine. In patients with mild renal impairment dose adjustment may be required, and in moderate or severe impairment the monthly injection is generally not recommended.
- Hepatic impairment: No dose adjustment is required for mild or moderate hepatic impairment; severe hepatic impairment has not been studied and caution is advised.
- Venous thromboembolism: Cases of venous thromboembolism (deep vein thrombosis and pulmonary embolism) have been reported with antipsychotics. All modifiable risk factors should be identified before and during treatment and preventive measures undertaken.
- Body temperature disruption: Antipsychotics may impair the body’s ability to regulate core temperature. Appropriate care is recommended in patients exposed to extreme heat, strenuous exercise, dehydration or anticholinergic co-medication.
- Intraoperative floppy iris syndrome (IFIS): Has been observed during cataract surgery in patients treated with medicines having alpha-1a adrenergic antagonist effect, including paliperidone. If you are undergoing eye surgery, inform your ophthalmologist.
- Suicide risk: The possibility of a suicide attempt is inherent in psychotic illnesses and some mood disorders. Close supervision of high-risk patients should accompany drug therapy.
Paliperidone can cause weight gain, hyperglycaemia and changes in blood lipids. Before and during treatment, your doctor should check your weight, waist circumference, fasting blood glucose or HbA1c, and lipid profile at regular intervals. If you already have diabetes, your blood glucose levels may need to be monitored more frequently.
Pregnancy, Breastfeeding and Fertility
If you are pregnant, planning to become pregnant, or breastfeeding, discuss this carefully with your doctor before starting or continuing Paliperidone Liconsa. Because the medicine persists in the body for weeks after each injection, decisions about use in pregnancy must consider not only the current dose but also residual plasma levels from prior injections.
Neonates exposed to antipsychotics (including paliperidone) during the third trimester of pregnancy are at risk of adverse reactions, including extrapyramidal symptoms and/or withdrawal symptoms such as agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorders, which may vary in severity and duration. Newborns should be monitored carefully. Untreated psychosis during pregnancy also carries substantial risks for both mother and child, so the decision to continue or suspend treatment must be individualised and made together with a specialist.
Paliperidone is excreted in breast milk in amounts that may affect a breastfed infant, particularly in newborns and premature babies. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from paliperidone therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the woman.
Paliperidone raises prolactin levels, which may cause menstrual irregularities, reduced libido and fertility effects in women, and sexual dysfunction and decreased sperm quality in men. Patients planning pregnancy should discuss these effects with their clinician.
Driving and Operating Machinery
Paliperidone may cause somnolence, sedation, dizziness, blurred vision and syncope. Patients should be advised not to drive or operate machinery until their individual susceptibility to these effects is known. These effects may be particularly noticeable after the first few injections, at dose changes, in the elderly, or in combination with other CNS depressants or alcohol.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is, essentially “sodium-free”. Refer to the current package leaflet for the full list of excipients.
How Does Paliperidone Liconsa Interact with Other Drugs?
A practical advantage of paliperidone compared with some other antipsychotics is that it is only minimally metabolised by hepatic cytochrome P450 enzymes. Around 60% of an administered dose is excreted unchanged in the urine, and metabolic pathways (including CYP2D6 and CYP3A4) contribute relatively modestly. As a result, paliperidone has a reasonably clean profile with respect to pharmacokinetic drug interactions. Pharmacodynamic interactions – those based on overlapping effects on the central nervous system, cardiovascular system, or dopamine pathways – are, however, clinically important and must be considered carefully.
Drugs That May Reduce Paliperidone’s Effect
The following agents can decrease paliperidone plasma concentrations, potentially leading to reduced efficacy:
| Interacting Drug / Class | Mechanism | Clinical Recommendation |
|---|---|---|
| Carbamazepine (antiepileptic, mood stabiliser) | Potent inducer of CYP3A4 and P-glycoprotein; reduces paliperidone exposure | Re-evaluate dose when starting or stopping carbamazepine; dose increases may be needed |
| Rifampicin (antibiotic, tuberculosis) | Strong enzyme inducer; lowers paliperidone plasma levels | Monitor clinical response; dose adjustment may be required |
| Phenytoin, phenobarbital (antiepileptics) | Hepatic enzyme induction; may decrease paliperidone exposure | Individualise dosing and monitor for symptom worsening |
| St John’s wort (Hypericum perforatum) | CYP3A4 and P-glycoprotein induction; may reduce paliperidone levels | Avoid concomitant use; discuss any herbal products with your doctor |
| Smoking (tobacco) | Modest induction of some metabolic pathways; clinical effect generally limited | No routine dose change; significant changes in smoking status should be discussed with your prescriber |
Pharmacodynamic Interactions
Pharmacodynamic interactions – those involving shared biological effects – are typically more clinically important for paliperidone than pharmacokinetic ones:
| Interacting Drug / Class | Potential Effect | Clinical Recommendation |
|---|---|---|
| CNS depressants (benzodiazepines, opioids, sedating antihistamines, some antiepileptics) | Additive sedation, impaired cognition, respiratory depression | Use only when clearly indicated; choose lowest effective doses; caution with driving |
| Alcohol | Increased sedation, impaired judgement, potential worsening of psychiatric illness | Avoid or strictly limit alcohol during treatment |
| Antihypertensive agents | Additive blood pressure lowering and orthostatic hypotension | Monitor blood pressure, particularly when starting or adjusting doses |
| QT-prolonging medicines (class IA/III antiarrhythmics, some antibiotics, antifungals, methadone, certain antidepressants) | Additive QT-interval prolongation and risk of torsade de pointes | Use with caution; consider ECG monitoring; review electrolytes (particularly potassium and magnesium) |
| Levodopa and other dopamine agonists | Mutual antagonism: paliperidone may reduce antiparkinson effect; dopamine agonists may worsen psychosis | Avoid where possible; use only with specialist input in Parkinson’s disease or similar conditions |
| Seizure-threshold-lowering drugs (tramadol, bupropion, some antibiotics) | Additive reduction in seizure threshold | Use cautiously, particularly in patients with a history of seizures |
| Other antipsychotics or agents affecting the dopaminergic system | Additive risk of extrapyramidal symptoms, neuroleptic malignant syndrome and metabolic effects | Combination antipsychotic therapy should be reserved for specialist-led care |
Once Paliperidone Liconsa has reached steady state, concomitant daily oral paliperidone or oral risperidone is generally unnecessary and may increase the risk of adverse effects. Your psychiatrist will plan any cross-titration carefully and should not continue oral paliperidone/risperidone beyond the transition period unless clinically justified.
What Is the Correct Dosage of Paliperidone Liconsa?
Paliperidone Liconsa must be administered by a healthcare professional familiar with the correct injection technique. It is injected intramuscularly into the deltoid or gluteal muscle and must not be given intravenously or subcutaneously. The syringe is supplied ready-to-use with safety-engineered needles; the content must be shaken vigorously for at least 10 seconds immediately before administration to form a uniform suspension. Once administered, the injection cannot be retrieved; decisions about dose and injection site therefore need careful planning.
Initiation Schedule (Adults)
In patients not already receiving the long-acting injection, treatment is started with two deltoid loading doses:
| Visit | Dose | Site | Notes |
|---|---|---|---|
| Day 1 | 150 mg | Deltoid | First loading dose; ensures rapid onset of therapeutic plasma levels |
| Day 8 (±2 days) | 100 mg | Deltoid | Second loading dose; completes the initiation phase |
| Day 36 onwards (monthly) | 25–150 mg | Deltoid or gluteal | Recommended maintenance dose 75 mg for most adults; range 25–150 mg individualised |
Maintenance Therapy and the Role of 25 mg
Where Paliperidone Liconsa 25 mg Fits
After the initiation phase, the recommended monthly maintenance dose in most adults is 75 mg. Some patients benefit from lower or higher doses within the 25–150 mg range, depending on tolerability and response. The 25 mg dose is the lowest strength of the monthly formulation and is typically considered in the following situations:
- Patients with mild renal impairment (creatinine clearance 50 to <80 mL/min), where reduced initiation and maintenance doses are recommended.
- Patients who have responded well at low paliperidone plasma concentrations during prior oral treatment.
- Patients in whom higher maintenance doses have caused dose-related side effects such as extrapyramidal symptoms, marked sedation, orthostatic hypotension or hyperprolactinaemia.
- Specific clinical scenarios discussed between patient and psychiatrist in whom a low exposure is preferred.
Dose adjustment, when required, should be made no more frequently than every month; because of the prolonged apparent half-life of paliperidone after injection, the full clinical effect of a dose change may not be apparent until several months later.
Renal Impairment
Renal Impairment
Paliperidone is eliminated mainly by the kidneys. In mild renal impairment (creatinine clearance 50 to <80 mL/min), a reduced initiation schedule (100 mg on day 1 and 75 mg on day 8 in the deltoid) is typically used, with a recommended monthly maintenance dose of 50 mg (range 25–100 mg). In moderate to severe renal impairment (creatinine clearance <50 mL/min), the once-monthly injection is not recommended, and alternative treatment options should be considered.
Elderly Patients
Elderly Patients
In elderly patients with normal renal function, the same doses used in younger adults apply. Because renal function often declines with age, dose adjustment based on actual creatinine clearance is recommended, and a conservative approach to dose selection is appropriate. Paliperidone is not approved for dementia-related psychosis in elderly patients.
Children and Adolescents
Paediatric Use
The safety and efficacy of the once-monthly paliperidone palmitate injection in children and adolescents younger than 18 years have not been established. Paliperidone Liconsa is not recommended for paediatric use.
Switching from Other Antipsychotics
Paliperidone Liconsa can be used in patients previously treated with oral paliperidone, oral risperidone, long-acting injectable risperidone (Risperdal Consta) or other antipsychotics. Switching strategies vary:
- From oral paliperidone or oral risperidone: Standard initiation schedule; oral medication can generally be stopped at the time of the first injection.
- From long-acting risperidone injection: Start Paliperidone Liconsa in place of the next scheduled injection; continue monthly thereafter. No oral supplementation is normally required.
- From other oral antipsychotics: The previous oral antipsychotic is usually continued for a period while the initiation schedule achieves therapeutic plasma levels, then tapered off.
Missed Dose
Contact your psychiatric team if an injection is going to be delayed. Management depends on how long it has been since the last injection: if the delay is up to around one week beyond the scheduled date, the usual maintenance dose can typically be given on the next available day. Longer delays – especially beyond 6 weeks from the last monthly injection – may require a re-initiation schedule with deltoid dosing to restore therapeutic plasma levels. Never attempt to “catch up” by self-adjusting the dose.
Overdose
Because Paliperidone Liconsa is administered by a healthcare professional, accidental overdose is uncommon but may occur if an unintentionally high dose is given or if plasma levels rise because of unrecognised renal impairment or drug interactions. Symptoms of paliperidone overdose may include marked drowsiness, sedation, fast or irregular heartbeat, low blood pressure, prolonged QT interval, extrapyramidal symptoms, and in severe cases seizures, respiratory depression or loss of consciousness. If overdose is suspected, seek emergency medical care and contact your local poison information centre.
There is no specific antidote for paliperidone. Management is supportive and includes airway protection, continuous cardiac and blood pressure monitoring (with particular attention to QT prolongation and arrhythmia), intravenous fluids and sympathomimetic agents for hypotension (avoiding epinephrine/adrenaline alone, which can worsen hypotension through unopposed alpha blockade), and standard supportive measures for seizures. Because plasma concentrations persist for weeks after injection, monitoring may need to continue for an extended period.
What Are the Side Effects of Paliperidone Liconsa?
As with all antipsychotic medicines, paliperidone palmitate can cause adverse effects, though not all patients will experience them. Most side effects are mild to moderate and resolve or improve with time; however, because the formulation is long-acting, effects that do occur may persist for longer than with daily oral medication. This underlines the importance of prior oral tolerability testing before initiating the depot form, regular review at each monthly injection, and prompt communication of any new or worrying symptoms.
The side effects below are grouped by frequency categories according to the MedDRA convention used in European prescribing information. Not every patient will experience any of these; conversely, rare effects listed here have been observed in clinical trials or post-marketing surveillance.
Contact your doctor or emergency services urgently if you experience: signs of neuroleptic malignant syndrome (high fever with muscle rigidity, sweating, rapid heartbeat, confusion or reduced consciousness); signs of severe allergic reaction (swelling of the face, lips, tongue or throat, difficulty breathing, sudden rash, low blood pressure); suspected stroke (sudden weakness, numbness, facial droop, slurred speech); signs of blood clots (painful leg swelling, chest pain, sudden shortness of breath); prolonged painful erection (priapism); severe high blood sugar (excessive thirst and urination, drowsiness, confusion); or new-onset fainting, seizures or irregular heartbeat.
Very Common
May affect more than 1 in 10 people
- Insomnia (difficulty falling or staying asleep)
- Headache
- Upper respiratory tract infection
- Injection-site reactions (pain, induration, redness)
Common
May affect up to 1 in 10 people
- Weight gain, increased or decreased appetite
- Anxiety, depression, agitation
- Extrapyramidal disorders: parkinsonism (rigidity, slow movements, tremor, reduced facial expression, drooling), akathisia (inner restlessness, inability to sit still), dystonia (involuntary muscle contractions), dyskinesia
- Somnolence, sedation, dizziness
- Tachycardia, palpitations, hypertension
- Blurred vision
- Cough, nasal congestion, pharyngitis
- Abdominal pain or discomfort, nausea, vomiting, constipation, diarrhoea, dry mouth, toothache
- Musculoskeletal pain, back pain, muscle spasms, arthralgia
- Rash
- Elevated blood glucose, elevated prolactin-related effects (breast enlargement, galactorrhoea, menstrual changes, sexual dysfunction)
- Fatigue, asthenia, peripheral oedema, pyrexia
Uncommon
May affect up to 1 in 100 people
- Anaemia, low white blood cell count, low platelet count
- Hypersensitivity reactions
- Diabetes mellitus or worsening of diabetes, hypercholesterolaemia, hypertriglyceridaemia
- Tardive dyskinesia, seizures, syncope, postural dizziness, tremor
- QT prolongation on ECG, atrial fibrillation, bundle branch block
- Orthostatic hypotension, hypotension
- Dyspnoea, wheeze, epistaxis, dysphonia
- Faecal incontinence, dysphagia, flatulence
- Urticaria, pruritus, alopecia, eczema, dry skin, acne
- Urinary incontinence, dysuria, amenorrhoea, erectile dysfunction, ejaculation disorders
- Gynaecomastia, breast discomfort or swelling
- Elevated hepatic enzymes (ALT, AST)
- Reduced bone mineral density with long-term elevated prolactin
Rare
May affect up to 1 in 1,000 people
- Agranulocytosis (very low white blood cell count)
- Inappropriate secretion of antidiuretic hormone (SIADH)
- Diabetic ketoacidosis, hyperosmolar coma
- Hypoglycaemia
- Neuroleptic malignant syndrome
- Catatonia
- Cerebrovascular events, coma
- Pulmonary embolism, deep vein thrombosis
- Aspiration pneumonia, pulmonary congestion
- Pancreatitis, intestinal obstruction, ileus
- Angioedema, Stevens-Johnson syndrome, toxic epidermal necrolysis
- Rhabdomyolysis
- Priapism
- Hypothermia
- Glaucoma, intraoperative floppy iris syndrome
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Severe injection-site reactions (nodule, abscess, cellulitis)
Very Rare / Frequency Not Known
Reported in post-marketing surveillance
- Neonatal drug withdrawal syndrome
- Sudden death
- Severe cardiac arrhythmias, including torsade de pointes
- Anaphylactic reactions following injection
- Severe water intoxication
- Retinal vascular occlusion
Injection-Site Reactions
Injection-site reactions are among the most commonly reported adverse effects of any long-acting antipsychotic injection. With once-monthly paliperidone palmitate they are generally mild and short-lived and typically include local pain, induration, redness and, more rarely, pruritus, swelling or nodules. Reactions tend to be less frequent in the deltoid than in the gluteal site. Rotating injection sites, careful aseptic technique and correct technique by a trained professional minimise the risk.
Impact of the Long-Acting Formulation on Side Effects
Because paliperidone palmitate provides exposure for around a month from a single injection, side effects that do occur cannot be rapidly reversed by stopping the medicine. In clinical practice this means that:
- Low starting doses and careful titration (usually via prior oral trial) help identify tolerability issues before commitment to the depot.
- Adverse effects that emerge after an injection may persist for several weeks.
- Some delayed onset of symptoms is possible, and patients, families and caregivers should be familiar with the warning signs to watch for between injections.
How Should Paliperidone Liconsa Be Stored?
Because Paliperidone Liconsa is administered by healthcare professionals in a clinical setting, most storage responsibility rests with the pharmacy and healthcare facility. However, a basic understanding of correct storage is useful both for patients and for any shared-care arrangements:
- Temperature: Store below 30 °C (86 °F). The medicine should not be frozen; if a syringe has been inadvertently frozen, it must not be used.
- Light and moisture: Keep the pre-filled syringe in the original outer carton until use to protect from light.
- Child safety: Store out of the sight and reach of children, even though the injection is administered by healthcare staff.
- Expiry date: Do not use Paliperidone Liconsa after the expiry date printed on the carton and label. The expiry date refers to the last day of that month.
- Visual inspection: Before administration, the syringe should be shaken vigorously for at least 10 seconds to ensure a homogeneous suspension and should then be inspected for particulate matter or discoloration. If the suspension cannot be resuspended, if there are large visible particles or discolouration, the syringe should not be used.
- Disposal: Medicines should not be disposed of via wastewater or household waste. Unused medicine and waste should be disposed of in accordance with local pharmaceutical disposal requirements, which helps protect the environment.
What Does Paliperidone Liconsa Contain?
Paliperidone Liconsa 25 mg prolonged-release suspension for injection contains:
- Active substance: Paliperidone palmitate corresponding to 25 mg of paliperidone per pre-filled syringe (other strengths of the product are available for higher maintenance doses).
- Inactive ingredients (excipients): Typically polysorbate 20, polyethylene glycol (macrogol), citric acid monohydrate, disodium hydrogen phosphate anhydrous, sodium dihydrogen phosphate monohydrate, sodium hydroxide (for pH adjustment) and water for injections. Always refer to the most recent patient information leaflet and Summary of Product Characteristics for the authoritative list of excipients.
Paliperidone Liconsa is supplied as a pre-filled syringe with safety-engineered needles (typically one thin-walled 1½ inch 22 gauge needle and one thin-walled 1 inch 23 gauge needle, depending on injection site). The suspension is white to off-white when properly resuspended.
Generic Status and Bioequivalence
Paliperidone Liconsa is authorised as a generic medicine and has been shown to be bioequivalent to the reference paliperidone palmitate once-monthly injection (Xeplion/Invega Sustenna). Generic long-acting injectables use the same active substance at the same strength as the originator, are manufactured to the same pharmaceutical quality standards, and are expected to deliver equivalent clinical effects. Laboratorios Liconsa, the marketing authorisation holder, is a Spanish pharmaceutical manufacturer that produces a range of generic hospital and specialty products.
Frequently Asked Questions About Paliperidone Liconsa
Paliperidone Liconsa is a once-monthly long-acting depot injection. Treatment is usually started with two deltoid loading doses – 150 mg on day 1 and 100 mg on day 8 – followed by a monthly maintenance dose (typically 75 mg for most adults, with individual doses ranging from 25 mg to 150 mg) given every month in the deltoid or gluteal muscle. A window of a few days either side of the scheduled date is usually acceptable, but you should stay in close contact with your psychiatric team to ensure injections happen on time.
Paliperidone Liconsa is licensed for the maintenance treatment of schizophrenia in adults (18 years and older) who are already clinically stabilised on oral paliperidone or oral risperidone. In selected patients with known tolerability to oral paliperidone or risperidone, it may also be used for the treatment of acute schizophrenia without first stabilising on daily oral medication. It is not approved for dementia-related psychosis, and its use in children and adolescents has not been established.
Paliperidone Liconsa is a generic version of the once-monthly paliperidone palmitate injection originally marketed under the brand names Xeplion (in the European Union) and Invega Sustenna (in the United States and elsewhere). It contains the same active substance (paliperidone palmitate) at the same strengths and has been authorised on the basis of bioequivalence to the reference product. Clinically it is expected to provide the same efficacy and safety profile. If you are already stable on the brand-name product, discuss any switch with your psychiatrist before changing products.
The most frequently reported side effects include insomnia, headache, injection-site reactions (pain, swelling, redness), upper respiratory tract infections, weight gain, anxiety, movement-related symptoms such as parkinsonism and akathisia, sedation and elevated prolactin levels (which can affect menstruation, sexual function and breast tissue). Most side effects are mild to moderate and may improve over time, but because the medicine is long-acting, they can persist for several weeks after an injection. Talk to your clinical team about any new or troublesome symptoms.
Alcohol should be avoided or significantly limited during treatment with Paliperidone Liconsa. Both alcohol and paliperidone depress the central nervous system and can cause additive sedation, dizziness, impaired coordination and impaired judgement, all of which increase the risk of accidents, falls and injuries. Alcohol can also worsen mood, anxiety and psychotic symptoms, and may interact negatively with other medications you are taking. If you drink alcohol regularly, including heavy episodic use, be open about this with your psychiatrist so that treatment and any needed support can be planned safely.
Contact your psychiatric team as soon as you realise you will miss or have missed a scheduled injection. The recommended action depends on how long it has been since the last dose: small delays of up to around a week are often managed by administering the usual maintenance dose on the next suitable day, while longer gaps – especially beyond 6 weeks from the last monthly injection – may require a re-initiation schedule with deltoid injections to restore therapeutic plasma levels. Missing injections increases your risk of relapse, so consistent scheduling is one of the most important aspects of your treatment plan.
You should never stop Paliperidone Liconsa on your own without discussing it with your psychiatrist. Abrupt discontinuation of antipsychotic treatment is a major risk factor for relapse of schizophrenia and can be associated with withdrawal-like symptoms. In practice, because paliperidone persists in the body for weeks after a missed or stopped injection, there is a slow natural tapering effect, but this does not eliminate the risk of relapse. Any decision to stop, switch or reduce treatment should always be made together with your specialist team, with a plan for close clinical monitoring.
References
- European Medicines Agency (EMA). Xeplion (paliperidone palmitate) – Summary of Product Characteristics and European Public Assessment Report. Available at: www.ema.europa.eu/en/medicines/human/EPAR/xeplion
- U.S. Food and Drug Administration (FDA). Invega Sustenna (paliperidone palmitate) Prescribing Information. Available at: www.accessdata.fda.gov
- World Health Organization (WHO). Mental health – schizophrenia: key facts and guidance. WHO fact sheets. Geneva: WHO; 2024.
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3
- Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. doi:10.1016/S0140-6736(19)31135-3
- Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387-404. doi:10.1016/S2215-0366(21)00039-0
- Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117. doi:10.1016/j.schres.2009.10.026
- De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2012;8(2):114-126. doi:10.1038/nrendo.2011.156
- British National Formulary (BNF). Paliperidone. NICE Evidence Services. Updated 2025. Available at: bnf.nice.org.uk/drugs/paliperidone
- European Medicines Agency (EMA). Guideline on clinical investigation of medicinal products, including depot preparations, in the treatment of schizophrenia. EMA/CHMP/40072/2010 Rev.1.
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry and Clinical Pharmacology with documented academic background and clinical experience in long-acting injectable antipsychotic therapy.
Medical Review
iMedic Medical Review Board – Independent panel of physicians who verify medical accuracy, evidence quality, and adherence to international guidelines (WHO, EMA, FDA, NICE, BNF).
Evidence Standard
Level 1A evidence based on systematic reviews, meta-analyses and randomised controlled trials. GRADE evidence framework applied. No commercial funding and no pharmaceutical sponsorship.
Accessibility
Content reviewed for WCAG 2.2 Level AAA compliance. Optimised for screen readers, keyboard navigation, and assistive technology. High-contrast and reduced-motion support enabled.
Disclaimer: This article is for educational purposes only and does not replace professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider before starting, changing or stopping any medication.